臨床外科69巻6号

2014年06月発行

特集 癌の補助療法アップデート

胆道癌―補助化学療法についての今後の展望

著者： 深瀬耕二¹ 林洋毅¹ 片寄友¹ 海野倫明¹

所属機関： ¹東北大学病院肝胆膵外科

ページ範囲：P.712 - P.717

【ポイント】

◆現在，切除不能胆道癌の標準治療はゲムシタビン＋シスプラチン（GC）療法である．

◆術前・術後補助化学療法が有用であるというエビデンスはないが，術後補助化学療法の第Ⅲ相無作為比較試験が現在進んでいる．

◆今後の展開として，多剤併用療法の確立や分子標的薬の導入が期待されている．

参考文献

1）Miyakawa S, Ishihara S, Horiguchi A, et al：Biliary tract cancer treatment：5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 16：1-7, 2009

2）Valle J, Wasan H, Palmer DH, et al：Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362：1273-1281, 2010

3）Glimelius B, Hoffman K, Sjödén PO, et al：Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7：593-600, 1996

4）Takada T, Nimura Y, Katoh H, et al：Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma：multicenter randomized trial. Hepatogastroenterology 45：2020-2026, 1998

5）Okusaka T, Ishii H, Funakoshi A, et al：Phase Ⅱ study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 57：647-653, 2006

6）Sharma A, Dwary AD, Mohanti BK, et al：Best supportive care compared with chemotherapy for unresectable gall bladder cancer：a randomized controlled study. J Clin Oncol 28：4581-4586, 2010

7）Okusaka T, Nakachi K, Fukutomi A, et al：Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer：a comparative multicentre study in Japan. Br J Cancer 103：469-74, 2010

8）Furuse J, Okusaka T, Boku N, et al：S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer：a multicenter phase Ⅱ study. Cancer Chemother Pharmacol 62：849-855, 2008

9）Sasaki T, Isayama H, Nakai Y, et al：A randomized phase Ⅱ study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer. Cancer Chemother Pharmacol 71：973-979, 2013

10）Morizane C, Okusaka T, Mizusawa J, et al：Randomized phase Ⅱ study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer：a Japan Clinical Oncology Group trial （JCOG 0805）. Cancer Sci 104：1211-1216, 2013

11）Kang MJ, Lee JL, Kim TW, et al：Randomized phase Ⅱ trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. Acta Oncol 51：860-866, 2012

12）Takada T, Amano H, Yasuda H, et al：Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A Phase Ⅲ multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95：1685-1695, 2002

13）胆道癌診療ガイドライン作成出版委員会：エビデンスに基づいた胆道癌診療ガイドライン．医学図書出版，2007, pp 94-95

14）National Comprehensive Cancer Network （NCCN） Clinical Practice Guidelines in Oncology：Hepatobiliary Cancers version 2. 2013. ［http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf］

15）Lee J, Park SH, Chang HM, et al：Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer：a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 13：181-188, 2012

16）Malka D, Cervera P, Heurteau-Foulon S, et al：Gemcitabine and oxaliplatin （GEMOX） alone or with cetuximab in first-line treatment of advanced biliary cancers （ABC）：Exploratory analyses according to tumor KRAS/BRAF mutations and EGFR expression in a randomized phase Ⅱ trial（BINGO）. J Clin Oncol 31, 2013 （suppl；abstr 4127）

17）Bekaii-Saab T, Phelps MA, Li X, et al：Multi-institutional phase Ⅱ study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 29：2357-2363, 2011